Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9328226 | 0.83 | SIGMAR1 (0.56) | SIGMAR1CA1CA2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL8809245 | 0.83 | SIGMAR1 (0.56) | SIGMAR1CA1CA2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL8811592 | 0.83 | SIGMAR1 (0.56) | SIGMAR1CA1CA2CHRM2CHRM4 | |
| SCHEMBL9520305 | 0.83 | SIGMAR1 (0.55) | SIGMAR1CA1CA2 | |
| SCHEMBL7777522 | 0.82 | SIGMAR1 (0.57) | SIGMAR1 | |
| SCHEMBL9549201 | 0.81 | SIGMAR1 (0.57) | SIGMAR1CA1CA2CHRM2CHRM4 | |
| SCHEMBL8019430 | 0.81 | SIGMAR1 (0.57) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 | |
| SCHEMBL15839894 | 0.81 | SIGMAR1 (0.57) | SIGMAR1CA1CA2CHRM2CHRM4 | |
| SCHEMBL15286771 | 0.81 | SIGMAR1 (0.57) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 | |
| SCHEMBL8811492 | 0.81 | SIGMAR1 (0.57) | SIGMAR1CHRM2CHRM4ABCB1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869013-A1 | SUBSTITUTED CHROMAN DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF ANTIPHLOGISTICS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
| WO-2006108711-A1 | SUBSTITUTED CHROMAN DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF ANTIPHLOGISTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | SIGMAR1 1559/4885CA1 3923/4885CA2 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.